Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Carcinoma, Renal Cell 127Kidney Neoplasms 39Neoplasms 37Neoplasm Metastasis 35Breast Neoplasms 33Gastrointestinal Stromal Tumors 27Carcinoma, Non-Small-Cell Lung 22Prostatic Neoplasms 16Urinary Bladder Neoplasms 13Colorectal Neoplasms 12Brain Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Carcinoma, Hepatocellular 11Melanoma 10Lung Neoplasms 10Stomach Neoplasms 8Neuroendocrine Tumors 8Carcinoma 8Thyroid Neoplasms 7Sarcoma 7Ovarian Neoplasms 7Multiple Myeloma 7Liver Neoplasms 7Small Cell Lung Carcinoma 6Leukemia, Myeloid, Acute 6Glioma 6Esophageal Neoplasms 6Adenoma, Islet Cell 6Uveal Melanoma 5

Interventions

Carboplatin 158Paclitaxel 152Bevacizumab 85Gemcitabine 48liposomal doxorubicin 47Taxes 47Topotecan 41Cisplatin 34pembrolizumab 33Cyclophosphamide 28olaparib 25Immunoglobulin G 24Disulfides 24Specimen Handling 20Docetaxel 20Drug Therapy 19Magnetic Resonance Spectroscopy 17niraparib 16Doxorubicin 16Biopsy 15mirvetuximab soravtansine 14Hyperthermic Intraperitoneal Chemotherapy 13rucaparib 12Nivolumab 12Cytoreduction Surgical Procedures 10Albumin-Bound Paclitaxel 10veliparib 9Platinum 9Chemotherapy, Adjuvant 9130-nm albumin-bound paclitaxel 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Fallopian Tube Neoplasms × Sunitinib × Clear all
NCT00768144 2018-08-24

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Dana-Farber Cancer Institute

Phase 2 Completed
36 enrolled 10 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00388037 2015-01-27

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
31 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00543049 2014-03-07

Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor

AGO Study Group

Phase 2 Completed
73 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡